Abstract: This invention relates to compositions, including oral care compositions, comprising naringin-loaded metal-organic frameworks (MOFs), such as naringin-loaded MIL-101(Fe), as well as methods of using and of making these compositions.

Abstract: Personal care compositions including a naringin:zinc complex and methods for preparing and using the same are provided. The personal care compositions may include a carrier and a naringin:zinc complex having a 2:1 naringin to zinc molar ratio.

Abstract: A non-cariogenic carbonated beverage is provided comprising carbonated water, a food-grade basic buffer and at least one amino acid.

Abstract: Personal care compositions including a naringin:zinc complex and methods for preparing and using the same are provided. The personal care compositions may include a carrier and a naringin:zinc complex having a 2:1 naringin to zinc molar ratio.

Abstract: Disclosed herein are oral care compositions comprising naringin:Zinc complexes having a 2:1 naringin to zinc molar ratio. Methods of making and using the compositions are also provided.

Abstract: Disclosed herein are oral care compositions comprising naringin:Zinc complexes having a 2:1 naringin to zinc molar ratio. Methods of making and using the compositions are also provided.

Abstract: Disclosed herein are oral care compositions comprising naringin:Zinc complexes having a 2:1 naringin to zinc molar ratio. Methods of making and using the compositions are also provided.

Abstract: Disclosed herein are oral care compositions comprising naringin:Zinc complexes having a 2:1 naringin to zinc molar ratio. Methods of making and using the compositions are also provided.

Abstract: The present invention relates to pharmaceutical compositions comprising a prostacyclin, a cationic compound, and a surfactant. Particulate compositions, including liposomal, solid nanoparticulate prostacyclin compositions, including treprostinil formulations comprising cationic compound and the surfactant are also described. The present invention also relates to a system comprising the pharmaceutical composition and an inhalation device. Methods for treating pulmonary hypertension and portopulmonary hypertension with the compositions and systems described herein are also provided.

Abstract: Provided is a method of treating a proliferative disease, condition, or disorder in a subject by administering a combination of an inhibitor of p53 and MDM2 binding and an EGFR inhibitor. Various embodiments of the disclosed methods provide a synergistic anti-proliferative or anti-apoptotic effect compared to administration of one agent alone.

Abstract: Provided herein are compounds having anti-proliferative effect. Also provided are compounds that can modulate the activity of multi-domain proteins comprising a dimerization arm and interdomain tether, such as EGFR, where an untethered, extended conformation is the active state and a tethered conformation is the inactive state, resulting in an autoinhibited configuration. Also provided are methods and pharmacophores for identifying such compounds. Other aspects provide methods or therapeutic treatment for proliferative diseases, disorders, or conditions, such as those associated with EGFR.

Abstract: Provided is a method of treating a proliferative disease, condition, or disorder in a subject by administering a combination of an inhibitor of p53 and MDM2 binding and an EGFR inhibitor. Various embodiments of the disclosed methods provide a synergistic anti-proliferative or anti-apoptotic effect compared to administration of one agent alone.

Abstract: Provided herein are compounds having anti-proliferative effect. Also provided are compounds that can modulate the activity of multi-domain proteins comprising a dimerization arm and interdomain tether, such as EGFR, where an untethered, extended conformation is the active state and a tethered conformation is the inactive state, resulting in an autoinhibited configuration. Also provided are methods and pharmacophores for identifying such compounds. Other aspects provide methods or therapeutic treatment for proliferative diseases, disorders, or conditions, such as those associated with EGFR.